New Malaria Vaccine PfSPZ-LARC2 Shows 87% Efficacy in Phase 1 Trial

An experimental malaria vaccine, PfSPZ-LARC2, prevented infection in 87% of vaccinated volunteers in a phase 1 trial whose results were presented Thursday in Washington, D.C. Researchers at UW Medicine exposed participants to live parasites 12 to 16 weeks after vaccination; all seven placebo recipients became infected, while only two of 15 vaccinated volunteers did.

The findings, reported by Dr. Sean C. Murphy, who holds a professorship in laboratory medicine and pathology at the University of Washington School of Medicine and serves as medical director of the Department of Laboratories at Seattle Children’s Hospital, were shared at the yearly gathering of the American Society of Tropical Medicine and Hygiene.

The trial was conducted by UW Medicine and its partners as part of the Infectious Diseases Clinical Research Consortium and was sponsored by the National Institute of Allergy and Infectious Diseases, enrolling participants beginning in the summer of 2025.

Why this matters: malaria kills more than 600,000 people worldwide each year, and the parasites that cause it — Plasmodium falciparum among them — are geographically diverse, so a vaccine that works in one region may fail in another. This trial was built to test both problems at once.

The vaccine strain originated in West Africa; the challenge strain used to test the volunteers came from Brazil. Protection held across that divide, and it held months after the final dose — a signal of durable, cross-strain immunity rather than a short-lived response.

New Malaria Vaccine PfSPZ-LARC2 Shows 87% Efficacy in Phase 1 Trial
Photo: bioengineer.org

“We engineered the PfLARC2 strain with the goal to have a safe vaccine that stimulates a superior response against malaria parasite infection in the liver. It is truly rewarding to see that this vaccine is safe and how well it has protected against challenge with a highly divergent malaria strain in the Seattle trial,” said Dr. Stefan Kappe, now director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, who created the attenuated strain in his laboratory at Seattle Children’s.

Weakened malaria parasite vaccine shows early efficacy signal

  • The vaccine is a weakened (live-attenuated) whole malaria parasite with two genes removed, so it grows normally in the liver — where infection begins — and then stops, training the immune system without causing disease.
  • In this small, early trial, 13 of 15 vaccinated volunteers stayed infection-free after deliberate exposure to a genetically different parasite strain months later.
  • This is a phase 1 result: it establishes safety and a promising efficacy signal, not approval. Larger trials in malaria-endemic regions must come next.

How the challenge trial worked

The study used a controlled human malaria infection design — volunteers are deliberately exposed to live parasites under carefully monitored conditions, with prompt treatment available. All participants who became infected were safely and promptly treated, News-Medical reported.

The design is possible in Seattle, Dr. Jim Kublin of the Fred Hutch Cancer Center’s Vaccine and Infectious Disease Division noted, because the city has a unique testing facility and an altruistic study population; UW Medicine and Fred Hutch teams have run malaria human challenge studies there since 2011.

The trial’s rigor comes from two deliberate hurdles. First, the 12-to-16-week gap between the last dose and exposure tested whether immunity persists — many vaccine candidates look strong only when tested immediately.

Second, using a Brazilian challenge strain against a West African vaccine strain tested whether protection crosses the genetic diversity that makes P. falciparum so hard to defeat. bioengineer.org’s report of the trial said that this geographically discordant design was engineered specifically to evaluate cross-strain protection.

New Malaria Vaccine PfSPZ-LARC2 Shows 87% Efficacy in Phase 1 Trial
Photo: miragenews.com

What the numbers show

The efficacy figure derives from a small cohort, so the table below keeps the raw counts in view. With 22 participants, wide confidence intervals around any percentage are expected — a limitation the sources describe as inherent to the phase 1 design.

The vaccine was reported as safe and well tolerated in the vaccinated group. The co-principal investigators, alongside Murphy, were Dr. Kublin and Dr. R. Scott McClelland, who teaches medicine, epidemiology and global health at UW School of Medicine and oversaw clinical site operations at Harborview Medical Center’s Virology Research Clinic.

“This study was made possible by the culmination of decades’ worth of research on the biology of Plasmodium parasites and the maturation of genetic engineering technologies that allowed scientists to modify the parasite genome to make it safe for use in humans and yet tuned just right to induce strong protective immune responses,” said Dr. Sean C. Murphy.

Who funded it, and who stands to gain

Funding transparency matters for any vaccine story. The trial was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, under the Infectious Diseases Clinical Research Consortium (award UM1AI148684) and the University of Washington’s Vaccine and Treatment Evaluation Unit (UM1AI148573).

The vaccine candidate itself was developed, manufactured and advanced to the clinical stage by Sanaria Inc., a Rockville, Maryland biotechnology company focused on whole-parasite PfSPZ vaccines — meaning a commercial entity holds a stake in the product’s future even though the trial was federally funded and run by an academic consortium.

Us malaria vaccine showed percent eff
Photo: ua.news

From Seattle to the clinic

A phase 1 result, however encouraging, is not a licensed product. The path forward runs through larger phase 2 and 3 trials, typically conducted in the regions where malaria actually transmits — sub-Saharan Africa above all — before any regulator such as the FDA in the United States, the EMA in Europe, or national authorities in endemic countries could consider authorization.

Existing licensed malaria vaccines, including the WHO-recommended RTS,S and R21 candidates, reduce severe disease and deaths; a vaccine that blocks infection outright, as this one aims to do, would add a different and complementary tool, since preventing infection also prevents transmission. None of the sources report a timeline for such trials, and that remains an open question.

Contraindications & When to Consult a Doctor

PfSPZ-LARC2 is investigational. It is not available outside clinical trials, and no member of the public can request it; travelers and residents of endemic areas should rely on currently approved preventives and consult a travel-medicine clinician. As a live-attenuated product, its safety in pregnant or immunocompromised people — groups for whom live vaccines often carry contraindications — has not been established by these sources, and phase 1 cohorts rarely include them.

Anyone exposed to malaria who develops fever, chills, or flu-like illness within weeks of travel to an endemic region should seek medical evaluation promptly, since early treatment of actual infection is highly effective. All infections in this trial were treated safely and promptly, which is precisely how real-world malaria should be managed.

Engineered whole-parasite vaccine provides durable protection in trials

The result is a proof of concept, not a public health intervention yet. What it shows is that a genetically engineered whole-parasite vaccine can produce durable protection against a strain from another continent — the two hardest problems in malaria vaccinology — in a small, well-controlled setting.

The next evidence will need to come from the field, not the challenge clinic. As Murphy said of the Seattle platform, “We look forward to continuing to advance this vaccine and other promising products that can combat malaria using our unique clinical trial resources here in Seattle.”

UW Medicine, the organization behind the trial, grew out of the University of Washington School of Medicine, founded in 1946 as the 76th medical school in the country and the first public medical school serving Washington, Wyoming, Alaska, Montana and Idaho.

Through that five-state partnership, known as WWAMI, the school maintains teaching facilities in more than 100 towns and cities, and its programs have ranked first in the nation for primary care education. UW Medicine also operates Harborview Medical Center, University of Washington Medical Center and Airlift Northwest, a medical transport system spanning four states.

References

  • University of Washington School of Medicine/UW Medicine — press materials on the PfSPZ-LARC2 phase 1 trial (source of the primary report, via News-Medical)
  • Genetically engineered malaria vaccine demonstrates 87% efficacy in phase 1 trial
  • Malaria Vaccine Shows 87% Efficacy in Clinical Trial
  • US malaria vaccine shows 87% efficacy in phase 1 trial

Consult a qualified health professional about malaria prevention and treatment.

Photo of author

Health Desk

Health Desk at Archyde.

Indonesia’s Fire Emissions Reach Third-Highest Annual Volume on Record